Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
COVID-19 vaccine strategies must focus on severe disease and global equity.
McIntyre PB, Aggarwal R, Jani I, Jawad J, Kochhar S, MacDonald N, Madhi SA, Mohsni E, Mulholland K, Neuzil KM, Nohynek H, Olayinka F, Pitisuttithum P, Pollard AJ, Cravioto A. McIntyre PB, et al. Among authors: pitisuttithum p. Lancet. 2022 Jan 22;399(10322):406-410. doi: 10.1016/S0140-6736(21)02835-X. Epub 2021 Dec 16. Lancet. 2022. PMID: 34922639 Free PMC article. Review. No abstract available.
AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines.
Kent SJ, Cooper DA, Chhi Vun M, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S; AIDS Vaccine for Asia Network investigators and supporters. Kent SJ, et al. Among authors: pitisuttithum p. PLoS Med. 2010 Sep 21;7(9):e1000331. doi: 10.1371/journal.pmed.1000331. PLoS Med. 2010. PMID: 20877474 Free PMC article.
Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers.
Levine MM, Abdullah S, Arabi YM, Darko DM, Durbin AP, Estrada V, Jamrozik E, Kremsner PG, Lagos R, Pitisuttithum P, Plotkin SA, Sauerwein R, Shi SL, Sommerfelt H, Subbarao K, Treanor JJ, Vrati S, King D, Balasingam S, Weller C, Aguilar AO, Cassetti MC, Krause PR, Restrepo AMH. Levine MM, et al. Among authors: pitisuttithum p. Clin Infect Dis. 2021 Jun 1;72(11):2035-2041. doi: 10.1093/cid/ciaa1290. Clin Infect Dis. 2021. PMID: 32857836 Free PMC article.
Expanding research capacity and accelerating AIDS vaccine development in Asia.
Excler JL, Pitisuttithum P, Rerks-Ngarm S, Shao Y, Zhang L, Tamashiro H, Osmanov S; WHO-UNAIDS Regional Consultation. Excler JL, et al. Among authors: pitisuttithum p. Southeast Asian J Trop Med Public Health. 2008 Jul;39(4):766-84. Southeast Asian J Trop Med Public Health. 2008. PMID: 19058617
The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.
de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, Paris RM, Kaewkungwal J, Michael NL, Rerks-Ngarm S, Mathieson B, Marovich M, Currier JR, Kim JH; Ministry of Public Health–Thai AIDS Vaccine Evaluation Group Collaborators. de Souza MS, et al. Among authors: pitisuttithum p. J Immunol. 2012 May 15;188(10):5166-76. doi: 10.4049/jimmunol.1102756. Epub 2012 Apr 23. J Immunol. 2012. PMID: 22529301 Free PMC article. Clinical Trial.
The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.
Karasavvas N, Billings E, Rao M, Williams C, Zolla-Pazner S, Bailer RT, Koup RA, Madnote S, Arworn D, Shen X, Tomaras GD, Currier JR, Jiang M, Magaret C, Andrews C, Gottardo R, Gilbert P, Cardozo TJ, Rerks-Ngarm S, Nitayaphan S, Pitisuttithum P, Kaewkungwal J, Paris R, Greene K, Gao H, Gurunathan S, Tartaglia J, Sinangil F, Korber BT, Montefiori DC, Mascola JR, Robb ML, Haynes BF, Ngauy V, Michael NL, Kim JH, de Souza MS; MOPH TAVEG Collaboration. Karasavvas N, et al. Among authors: pitisuttithum p. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1444-57. doi: 10.1089/aid.2012.0103. Epub 2012 Oct 4. AIDS Res Hum Retroviruses. 2012. PMID: 23035746 Free PMC article. Clinical Trial.
Considerations for unblinding individual study participants during vaccine trials.
Halsey N, Evans S, Santosham M, Hacker A, Edwards KM, Chandler RE, Dudley MZ, Dekker CL; members of the SPEAC meta-DSMB; Al-Abri S, Arora N, Buttery J, Dodoo A, Eskola J, Heininger U, Jee Y, Khuri N, Obaro S, Orenstein W, Pitisuttithum P, Safadi M, Whitney CG, Black S. Halsey N, et al. Among authors: pitisuttithum p. Vaccine. 2023 May 22;41(22):3399-3402. doi: 10.1016/j.vaccine.2023.04.033. Epub 2023 Apr 28. Vaccine. 2023. PMID: 37121805 Free article. Review.
Single Ad26.COV2.S booster dose following two doses of BBIBP-CorV vaccine against SARS-CoV-2 infection in adults: Day 28 results of a phase 1/2 open-label trial.
Muangnoicharoen S, Wiangcharoen R, Nanthapisal S, Kamolratakul S, Lawpoolsri S, Jongkaewwattana A, Thitithanyanont A, Luvira V, Chinwangso P, Thanthamnu N, Chantratita N, Lim JK, Anh Wartel T, Excler JL, Ryser MF, Leong C, Mak TK, Pitisuttithum P. Muangnoicharoen S, et al. Among authors: pitisuttithum p. Vaccine. 2023 Jul 19;41(32):4648-4657. doi: 10.1016/j.vaccine.2023.06.043. Epub 2023 Jun 15. Vaccine. 2023. PMID: 37344265 Free PMC article. Clinical Trial.
226 results